http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
정신분열병 및 정신분열형 장애에 대한 올란자핀의 효과와 안전성
안용민,강대엽,권준수,김창윤,김철응,반건호,신영민,이기철,이동우,이중서,조현상,채정호,김용식 大韓神經精神醫學會 2001 신경정신의학 Vol.40 No.4
연구목적 : 본 다기관 공동임상연구는 국내 환자를 대상으로 새로운 항정신병약물인 올라자핀의 치료 효과와 안전성을 확인하고자 시행되었다. 방 법 : 1999년 7월부터 2000년 3월까지 국내 10개 병원에 방문한 정신분열병 및 정신분열형 장애 105명을 대상으로 비대조 개방 임상연구를 시행하였다. 중등도 이상의 정신병 증상을 지니거나, 부작용으로 약물교체가 필요한 경우 또는 기분장애 증상의 치료가 필요한 환자를 대상으로 하였다. 2∼7일간의 약물 배설기간 후에 1일 10mg의 올란자핀을 투여하였고, 이후로 3∼7일 간격으로 용량을 조절하여 총 8주간 투여하였다. 치료 효과는 PANSS(Positive and Negative Syndrome Scale), BPRS(Brief Psychiatric Rating Scale), CGI(Clinical Global Impression-Severity), MADRS(Montgomery-Asberg Depression Rating Scale), HAM-A(Hamilton Rating Scale for Anxiety)로 판정하였다. 안전성 평가는 자발적인 이상반응 보고, 활력징후와 혈액 검사 및 SAS(Simpson-Angus Scale), BARS(Barnes Akathisia Rating Scale), AIMS(Abnormal Involuntary Movement Scale)척도를 이용하였다. 결 과 : 105명중에서 85.7%인 90명이 8주간의 치료를 완료하였다. 평균 최빈 용량은 일일 16.1(±4.7)mg이었고, 종료시점에서의 BPRS전체 점수가 기저 상태에 비해 40%이상 감소된 반응군은 69.5%이었다. PANSS의 양성 증후군과 일반정신병리 뿐만 아니라 음성 증후군 소척도에서도 유의한 감소를 보였으며, 이 감소들은 치료 초기부터 나타나서 8주간 지속되었다. 43.8%의 피험자가 중등도 이상의 우울증상을 같이 지니고 있었으며, 올란자핀에 의해 MADRS와 HAM-A가 유의하게 감소하였다. 치료 기간 동안에 활력징후에는 뚜렷한 변화가 없었으나 체중은 8주간 지속적으로 증가하였다. SAS와 AIMS는 감소하였으며, 정좌불능증을 제외한 나머지 추체외로 증상의 발생비율도 낮았다. 임상적인 증상이나 징후를 동반하지 않는 ALT/SGPT의 상승을 보였지만 프로락틴을 포함하는 대부분의 혈액 검사상 뚜렷한 이상 변화는 없었다. 결 론 ; 비록 본 임상연구가 비대조 개방 임상연구로서 많은 제한점을 가지고 있지만, 올란자핀이 기존 약물에 내약성을 보이거나 기분증상을 동반하는 정신병에 치료 효과가 있었다. 그리고 기존 항정신병약물 치료시에 문제가 되었던 추체외로 증상과 고프르로락틴 혈증을 포함하는 대부분의 부작용면에서 안전성을 보여 주었다. Objective : This multicenter clinical trial was carried out to investigate the efficacy and the safety of olanzpine for the treatment of Korean patients. Mothod : 105 patients with schizophrenia and schizophreniform disorder, visited at 10 mental or university hospitals, had received an open and non-comparative treatment with olanzapine for 8 weeks. Patients had psychotic or depressive symptoms with the severity above moderate degree or intolerable side effects to previous antipsychotics. After a wash-out period of 2-7 days, 10mg olanzapine was prescribed initially to all the patients, and then the dosage could be adjusted within the range of 5-20mg/day of olanzapine by 3-7 days. Results : 90(85.7%) of 105 patients completed the 8-weeks trial and the mean modal dose of olanzapine was 16.1(±4.7%)mg/day. At the end of the trial, 73 patients(69.5%) were classified as responder, which was defined as 40% or more improvement in BPRS(Brief Psychiatric Rating Scale) score comparing to baseline. There was a significant reduction in the scores of PANSS(Positive and Negative Syndrome Scale)and subscales including negative symptom scores and CGI. Also weekly analysis showed that the reductions in scores were kept on for the whole period of the trial. 43.8% of all the patients had depressive symptoms at the baseline and total scores of MADRS(Montgomery-Asberg Depression Rating Scale) and HAM-A(Hamilton Rating Scale for Anxiety) were also reduced after the trials. Vital signs revealed no clinically significant changes but continuous weight gain was observed during the treatment with olanzapine. The scores of SAS(Simpson-Angus Scale) and AIMS(Abnormal Involuntary Movement Scale) for assessing the EPS(extrapyramidal symptoms)and tardive dyskinesia respectively were significantly decreased and only a few patients reported EPS as adverse events. Although mild and clinically non-significant of ALT/SGPT was observed, most laboratory parameters including plasma prolactin level showed to significant changes during the trial. Conclusions : Although this trial had many limitations because it was a non-comparative and open study, olanzapine showed high efficacy on the positive, negative and depressive symptoms in schizophrenia and schizophreniform disorder.In addition to that, olanzapine showed a substantially favorable safety profile, such as low incidence of EPS and hyperprolactinemia.
Development of siderostat control system for SDSS-V Local Volume Mapper
Hojae Ahn,Florian Briegel,Mingyu Jeon,Tom Herbst,Sumin Lee,Inhwan Jung,Changgon Kim,Jimin Han,Geon Hee Kim,Wolfgang Gaessler,Markus Kuhlberg,Tae-Geun Ji,Hyun Chul Park,Soojong Pak,Nicholas P. Konidari 한국천문학회 2022 天文學會報 Vol.47 No.1
Lee, Jung Geon,Ahn, Curie,Yoon, Sung-Chul,Park, Jong Hoon,No, Jin Ju,Moon, Chang Suk,Song, Eun Kyeung,Hwang, Yeong Hwan,Hwang, Dae Yeon,Kim, Yon Su,Han, Jin Suk,Kim, Suhnggwon,Lee, Jung Sang,Kim, Seun 한국유전학회 2002 Genes & Genomics Vol.24 No.3
Two genetic loci, PKD1 and PKD2, have been identified as being responsible for ADPKD, but the presence of an intrafamilial clinical diversity suggests that there are disease-modifying loci. We studied the associations between polymorphism in the ecNOS gene, which are known to be associated with chronic tubulointerstitial and vascular changes, and ADPKD progression in Korean patients. A total of 112 individuals who had ADPKD and 41 normal control subjects were genotyped by PCR-RFLP, the Glu298Asp variant of ecNOS gene was discriminated with MboI. The distribution of the alleles for the ecNOS Glu298Asp polymorphism in ADPKD was: G 88 %, T 12 %, which was similar to the result of Korean population (95:5, p = 0.128) but different from Western controls (65:35, p = 0.000). No differences were found between the CRF and the non-CRF groups (p = 1.000) or the early hypertension and the normotension groups (p = 1.000). In conclusion, our results suggest that the polymorphism at Glu298Asp of ecNOS has no association with the renal progression in Korean ADPKD patients.
ADPKD 낭종액에서의 사이토카인 Profile 에 대한 연구
이중건(Jung Geon Lee),안규리(Curie Ahn),윤성철(Sung Chul Yoon),박종훈(Jong Hoon Park),문창숙(Chang Suk Moon),노진주(Jin Ju No),송은경(Eun Kyeung Song),김연수(Yon Su Kim),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이정상(Jung Sang Lee 대한신장학회 2002 Kidney Research and Clinical Practice Vol.21 No.5
N/A N/A
MANET에서 CSP/FDR을 이용한 EAODV 라우팅 프로토콜 검증
안영아(Young-Ah Ahn),전철욱(Chul-Wook Geon),김일곤(Il-Gon Kim),이명선(Myoung-Sun Lee),최진영(Jin-Young Choi) 한국정보과학회 2004 한국정보과학회 학술발표논문집 Vol.31 No.1A
MANET에서 라우팅 경로가 설정되었다고 하더라도 노드의 이동성으로 인하여 네트워크의 끊김 현상이 발생하여 재라우팅을 해야 하는 오버헤드와 전송 지연이 발생한다. 이러한 문제를 해결하기 위하여 각 노드의 에너지를 기반으로 에너지 그룹을 형성하고, 반응적 라우팅 프로토콜인 AODV를 수정하여 EAODV(Energy aware ADODV)를 제안하고 이를 정형 기법을 통해 명세하고 항상 라우팅 패스를 찾는다는 속성을 검증한다.
Overexpression of mutant HSP27 causes axonal neuropathy in mice
Lee, Jinho,Jung, Sung-Chul,Joo, Jaesoon,Choi, Yu-Ri,Moon, Hyo Won,Kwak, Geon,Yeo, Ha Kyung,Lee, Ji-Su,Ahn, Hye-Jee,Jung, Namhee,Hwang, Sunhee,Rheey, Jingeun,Woo, So-Youn,Kim, Ji Yon,Hong, Young Bin,Ch BioMed Central 2015 JOURNAL OF BIOMEDICAL SCIENCE -BASEL- Vol.22 No.1
<P><B>Background</B></P><P>Mutations in heat shock 27 kDa protein 1 (HSP27 or HSPB1) cause distal hereditary motor neuropathy (dHMN) or Charcot-Marie-Tooth disease type 2 F (CMT2F) according to unknown factors. Mutant HSP27 proteins affect axonal transport by reducing acetylated tubulin.</P><P><B>Results</B></P><P>We generated a transgenic mouse model overexpressing HSP27-S135F mutant protein driven by Cytomegalovirus (CMV) immediate early promoter. The mouse phenotype was similar to dHMN patients in that they exhibit motor neuropathy. To determine the phenotypic aberration of transgenic mice, behavior test, magnetic resonance imaging (MRI), electrophysiological study, and pathology were performed. Rotarod test showed that founder mice exhibited lowered motor performance. MRI also revealed marked fatty infiltration in the anterior and posterior compartments at calf level. Electrophysiologically, compound muscle action potential (CMAP) but not motor nerve conduction velocity (MNCV) was reduced in the transgenic mice. Toluidine staining with semi-thin section of sciatic nerve showed the ratio of large myelinated axon fiber was reduced, which might cause reduced locomotion in the transgenic mice. Electron microscopy also revealed abundant aberrant myelination. Immunohistochemically, neuronal dysfunctions included elevated level of phosphorylated neurofilament and reduced level of acetylated tubulin in the sural nerve of transgenic mice. There was no additional phenotype besides motor neuronal defects.</P><P><B>Conclusions</B></P><P>Overexpression of HSP27-S135F protein causes peripheral neuropathy. The mouse model can be applied to future development of therapeutic strategies for dHMN or CMT2F.</P><P><B>Electronic supplementary material</B></P><P>The online version of this article (doi:10.1186/s12929-015-0154-y) contains supplementary material, which is available to authorized users.</P>
아티초크 유산균 발효물의 발효 전후의 항산화 활성에 관한 연구
안용후(Yong-Hu Ahn),오건(Geon Oh),이형재(Hyeong-Jae Lee),김희종(Hui-Jong Kim),권민지(Min-Ji Gwon),우은지(Eun-Ji Woo),권상철(Sang-Chul Kwon) 한국산학기술학회 2021 한국산학기술학회논문지 Vol.22 No.9
본 연구는 아티초크 추출물과 유산균을 이용하여 발효물을 제조하고 발효 전후의 pH, 산도, 항산화 효능 분석을 위한 목적으로 수행하였다. 실험에 사용된 시료는 아티초크 분쇄 분말과 건조된 아티초크 꽃 차를 구입하여 사용하였다. 아티초크 발효물의 pH 측정값은 발효 후 전체적으로 감소하였으며, 분쇄 분말의 pH 중에서 L. plantarum 로 발효한 것이 3.34±0.01에서 2.80±0.01로 감소하여 가장 낮은 pH를 나타냈다. 산도 측정값은 발효 후 전체적으로 증가하는 경향을 나타내었으며, 분쇄 분말의 산도 중에서 L. plantarum 로 발효한 것이 0.81±0.00 %에서 1.71±0.00 %로 가장 높았다. Folin-Denis법을 변형하여 총 폴리페놀 함량(㎎ GAE/g)을 측정한 결과 발효를 통해 분쇄 분말 72.10±0.30 ㎎ GAE/g에서 18.8 % 까지 증가되었다. DPPH radical 소거능(㎎ AEAC/g)은 발효를 통해 분쇄 분말 39.34±0.38 ㎎ AEAC/g에서 51.3 % 까지 증가하였다. 전체 조건에서 분쇄 분말의 총 폴리페놀 함량과 DPPH radical 소거능이 최댓값을 나타냈다. L. plantarum 발효물에서 L. fermentum 과 P. pentosaceus 에 비해 총 폴리페놀 함량과 DPPH radical 소거능이 낮은 결과를 나타내었다. 본 연구를 통해 기능성 화장품과 식품 산업의 천연물 소재로서의 활용 가치가 있음을 나타내었다. In this study, fermentation was carried out using artichoke extracts and lactobacillus. The purpose was to analyze pH, acidity, and antioxidant efficacy before and after fermentation. The materials used in the experiment were ground artichoke powder and dried artichoke flower tea. The pH of the artichoke fermented products decreased after fermentation, and the pH of the Crushing powder, fermented with L. plantarum, decreased from 3.34±0.01 to 2.80±0.01, showing the lowest pH among the samples. Acidity showed a tendency to increase overall after fermentation, and among the samples, the acidity of the pulverized powder, fermented with L. plantarum was the highest, increasing from 0.81±0.00 % to 1.71±0.00 %. The total polyphenol content assayed by the modified Folin-Denis method was increased in Crushing powder by fermentation to 18.8 % (72.10±0.30 ㎎ GAE/g). The DPPH radical scavenging activity in Crushing powder was increased by fermentation to 51.3 % (39.34±0.38 ㎎ AEAC/g). Under all conditions, the total polyphenol content and DPPH radical scavenging activity of the Crushing powder showed the highest values. Fermentation with increased amounts of L. plantarum showed lower total polyphenol content and DPPH radical scavenging activity compared to L. plantarum and P. pentosaceus. For statistical processing, Although this study indicated that it is valuable as a natural product material for the functional cosmetics and food industries.